Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial
| Autor: | Susan L. McElroy, Shishuka Malhotra, Paul E. Keck, Jeffrey A. Welge, James I. Hudson, Erik Nelson |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Placebo-controlled study Citalopram Severity of Illness Index Drug Administration Schedule Body Mass Index Double-Blind Method Binge-eating disorder Internal medicine Surveys and Questionnaires Severity of illness Outcome Assessment Health Care medicine Humans Obesity Bulimia Psychiatry Depressive Disorder Binge eating Titrimetry Hamilton Rating Scale for Depression Middle Aged medicine.disease Psychiatry and Mental health Eating disorders Antidepressant Female medicine.symptom Psychology Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | The Journal of clinical psychiatry. 64(7) |
| ISSN: | 0160-6689 |
| Popis: | Background: Binge-eating disorder is a newly recognized eating disorder characterized by recurrent episodes of binge eating without compensatory weight loss behaviors. It commonly cooccurs with depressive disorders and obesity. Citalopram is a highly selective serotonin reuptake inhibitor antidepressant. The purpose of this study was to assess the efficacy and safety of citalopram in the treatment of binge-eating disorder. Method: Thirty-eight outpatients with a DSM-IV diagnosis of binge-eating disorder were enrolled in the study between August 2000 and July 2001 and were randomly assigned to receive either citalopram (N = 19) or placebo (N = 19) in a 6-week, double-blind, flexible-dose (20-60 mg/day) study. The primary measure of efficacy was frequency of binge-eating episodes. Secondary measures included frequency of binge days, body mass index (BMI), weight, Clinical Global Impressions-Severity of Illness scale scores, Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) scores, Hamilton Rating Scale for Depression (HAM-D) scores, and response categories. The outcome measures were analyzed using 2 random regression methods, with a time trend analysis (primary analysis) and an endpoint analysis. In addition, response categories were analyzed using an exact trend test. Results: Compared with placebo-treated subjects, subjects receiving citalopram (mean dose of 57.9 mg/day) had a significantly greater rate of reduction in frequency of binge eating (p = .003), frequency of binge days (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|